Dong-E-E-Jiao Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Dong-E-E-Jiao Co Ltd with three other
companies in this sector in CHINA :
Sunflower Pharmaceutical Group Co Ltd
sales of 3.46 billion Chinese Renmimbi [US$534.06 million]
of which 168%
Guizhou Yibai Pharmaceutical Co., Ltd.
(3.41 billion Chinese Renmimbi [US$526.66 million]
of which 87%
was Medical Industry), and
Gan & Lee Pharmaceuticals Co Ltd
(3.36 billion Chinese Renmimbi [US$518.74 million]
of which 98%
was Biological products).
Sales were up sharply during the first
quarter of 2021 versus the previous year's first quarter.
During the first
quarter of 2021, sales at Dong-E-E-Jiao Co Ltd totalled
722.41 million Chinese Renmimbi.
an increase of 62.6%
from the 444.22 million Chinese Renmimbi in sales at the company during the first quarter of 2020.
There appears to be at least some degree of seasonality in the sales at Dong-E-E-Jiao Co Ltd: during 8 of the previous 9
years, sales were highest during the fourth quarter.
The exception to this was during 2019, when the
first quarter was the best quarter, accounting for
44% of sales (during that same year, the
fourth quarter accounted for 4% of sales).
Dong-E-E-Jiao Co Ltd reported sales of 3.41 billion Chinese Renmimbi (US$525.85 million)
December of 2020.
increase of 15.0%
versus 2019, when the company's sales were 2.96 billion Chinese Renmimbi.
Despite this increase, sales are still
below the level achieved in 2018, when Dong-E-E-Jiao Co Ltd
reported sales of 7.34 billion Chinese Renmimbi.
Sales of Pharmaceutical Industry saw an increase
that was more than double the company's growth rate: sales were up
45.1% in 2020, from
2.07 billion Chinese Renmimbi to 3.00 billion Chinese Renmimbi.
Not all segments of Dong-E-E-Jiao Co Ltd experienced an increase in sales in 2020:
sales of Other fell 87.2% to 111.02 million Chinese Renmimbi.